Présentation de l'entreprise
Valneva SE operates as a specialty vaccine company dedicated to the development, manufacturing, and commercialization of prophylactic vaccines designed to address infectious diseases with significant unmet medical needs. The firm specifically offers IXIARO, an inactivated vaccine derived from Vero cell culture that is indicated for active immunization against Japanese encephalitis. This entity functions within the Healthcare sector and the Biotechnology industry, positioning it as a developer of high-potential immunotherapeutics rather than a broad-service provider. The company currently maintains a market capitalization of $561.35M and generates annual revenue of $174.66M, supported by a workforce of 674 employees. These financial figures indicate that Valneva holds a mid-cap position within the biotechnology landscape, reflecting a scale that is substantial enough to fund specialized research but remains relatively small compared to large-cap pharmaceutical conglomerates.
Santé financière
Valneva SE reported a trailing twelve-month revenue of $174.66M, yet the company posted a net income of $-115,192,000 and an EBITDA of $-64,702,000 for the same period. The substantial gap between the positive revenue figure and the negative net income reveals a highly aggressive cost structure where operational expenses and research expenditures significantly outweigh current earnings potential. The company generated a free cash flow of $-49,673,376, which indicates that current cash generation is insufficient to cover capital expenditures and working capital requirements without external financing. In terms of profitability metrics, the gross margin stands at -10.2%, suggesting that cost of goods sold currently exceeds total revenue; the operating margin is -58.1%, highlighting significant overhead burdens; and the profit margin is -66.0%, confirming that the company is not yet profitable on a bottom-line basis. On the balance sheet, the company holds $109.65M in cash against $207.25M in total debt, resulting in a debt-to-equity ratio of 195.21, which characterizes the balance sheet as highly leveraged rather than conservative. Despite the high leverage, the current ratio of 2.38 indicates that the company possesses sufficient current assets to cover its short-term liabilities, suggesting adequate short-term liquidity management. The return on equity is -80.2% and the return on assets is -11.4%, metrics that reveal that management effectiveness is currently challenged by the company's developmental stage and ongoing cash burn rather than value creation.
Évaluation de la valorisation
The valuation metrics show a trailing P/E ratio of N/A due to negative earnings, while the forward P/E is 7.72, implying that the market is pricing in a future trajectory where earnings are expected to turn positive or stabilize significantly. The price-to-book ratio is 8.82, indicating that the market values the company at a substantial premium over its tangible book value, likely reflecting intangible assets such as intellectual property and pipeline potential. Alternative valuation measures include a price-to-sales ratio of 3.21 and an EV/EBITDA of -18.26, which suggests the market is willing to pay a high multiple for revenue despite the current lack of positive earnings before interest, taxes, depreciation, and amortization. Regarding price metrics, the stock reached a 52-week high of $12.25 and a 52-week low of $5.43; without a specific current price provided in the source data, the valuation relative to this historical range cannot be precisely calculated, though the wide spread indicates significant price volatility over the last year. The beta value of 1.53 signifies that the stock is expected to be 53% more volatile than the broader market, meaning price movements will likely be amplified by general market shifts.
Growth & Income
The revenue growth year-over-year is -9.9%, while the earnings growth year-over-year is N/A due to the negative net income position. Since earnings are currently negative, a traditional comparison of earnings growth versus revenue growth is not applicable, but the decline in revenue suggests a contraction in commercial sales or a reduction in the company's market footprint. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, which confirms that the firm reinvests all available resources into research and development rather than distributing cash to shareholders. Consequently, the overall growth and income profile is characterized by a focus on capital preservation and future product launches rather than current income generation or dividend distribution.